Maze Therapeutics Inc. (MAZE)
Company Description
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.
Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease.
Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018.
The company was incorporated in 2017 and is based in South San Francisco, California.
| Country | United States |
| IPO Date | Jan 31, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 125 |
| CEO | Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. |
Contact Details
Address: 171 Oyster Point Blvd South San Francisco, California United States | |
| Website | https://www.mazetx.com |
Stock Details
| Ticker Symbol | MAZE |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001842295 |
| CUSIP Number | n/a |
| ISIN Number | US5787841007 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. | Chief Executive Officer & Director |
| Amy Bachrodt | Senior Vice President of Finance & Chief Financial Officer |
| Atul Dandekar | Chief Strategy & Business Officer |
| Courtney J. Phillips J.D. | General Counsel & Corporate Secretary |
| Dr. Harold S. Bernstein M.D., Ph.D. | President of Research & Development and Chief Medical Officer |
| Maarten Hoek | Senior Vice President of Research |
| Matt Krause | Senior Vice President of Human Resources |
| Nazila Habibizad | Senior Vice President of Technical Operations & Supply Chain |
| Vipin Vijayakumar | Vice President of R&D Infrastructure and Operations |
| Winston Tse | Senior Vice President of Drug Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13G | Filing |
| May 09, 2025 | SCHEDULE 13G | Filing |
| May 09, 2025 | SCHEDULE 13G | Filing |
| Apr 29, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 29, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Mar 31, 2025 | 10-K | Annual Report |